View Exam | PowerPak

1. Which one of the following statements is TRUE regarding inflammatory bowel disease (IBD):

A. Inactive disease is a common patient characteristic for those with IBD and anemia B. Decreased iron absorption is a risk factor for developing iron deficiency anemia (IDA) for patients with IBD C. B12 deficiency is the most common form of anemia for patients with IBD D. IBD is most common in developing countries in South American and Australia

2. Which oral iron regimen would deliver the low-dose supplementation of 50 to 120 mg of elemental iron per day?

A. Ferrous fumarate 325 mg by mouth (PO) twice daily B. Ferrous sulfate 325 mg; take 2 tabs PO twice daily C. Ferrous gluconate 325 mg; take 2 tabs PO 4 times daily D. Ferrous gluconate 325 mg PO twice daily

3. What dose of oral iron would you recommend for a patient with IDA when oral therapy is indicated?

A. Ferrous fumarate 325 mg PO once daily B. Ferrous fumarate 150 mg; 2 tabs PO twice daily C. Ferrous sulfate 325 mg; 2 tabs PO twice daily D. Ferrous gluconate 325 mg; 2 tabs PO twice daily

4. Which one of the following beverages is most appropriate to take with oral iron supplements:

A. Orange juice B. Milk C. Tea D. Coffee

5. Which IV iron formulation requires the most infusions to complete the total cumulative dose?

A. Ferric carboxymaltose B. Ferumoxytol C. Iron sucrose D. Ferric gluconate

6. Which IV iron formulation requires a test dose prior to the full dose?

A. Ferric carboxymaltose B. Ferumoxytol C. Iron sucrose D. Low molecular weight (LMW) iron dextran

7. A woman, 28 years of age, with active Crohn's Disease is admitted to the hospital and is diagnosed with IDA. The team has started appropriate induction therapy for the flare-up of disease, but the doctor would like you to recommend an iron replacement regimen. The patient weighs 60 kg, has a hemoglobin of 9.1 g/dL, a ferritin of 20 µg/L, and a transferrin saturation of 15%.

A. Ferrous fumarate 325 mg PO once daily B. Ferrous sulfate 325 mg PO twice daily C. Iron sucrose 200 mg IV as 5 different infusions over a 14 day period D. Ferric carboxymaltose 1000 mg IV daily for 5 days

8. A patient with IBD is started on oral iron replacement for mild IDA. Which one of the following lab values would indicate an appropriate response:

A. Hemoglobin increase by > 2 g/dL 1 week after therapy is initiated B. Hemoglobin value of 14 g/dL after 4 weeks of therapy C. Hemoglobin increase by ≥ 2 g/dL and transferrin saturation > 30%, 4 weeks of therapy D. Hemoglobin increase by ≥ 1 g/dL and transferrin saturation of 25%, 6 weeks of therapy

9. Which of the following would be an appropriate use of erythropoietin for the treatment of patients with IDA:

A. Add erythropoietin to oral iron supplementation to enhance the response B. Use erythropoietin in combination with IV iron as initial therapy upon the first diagnosis of IDA C. Use erythropoietin as monotherapy for the treatment of IDA D. Add erythropoietin to IV iron after nonresponse to IV iron monotherapy